Epigenic Therapeutics Appoints Dr. Chloe You as Chief Medical Officer and Dr. Kelly Shi as Chief Financial Officer to Bolster Global Clinical Development and Capital Strategy
Shanghai, China, March 3, 2026 — Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the appointments of Dr. Chloe You as Chief Medical Officer (CMO) and Dr. Kelly Shi as Chief Financial Officer (CFO). Dr. Chloe You will oversee the company’s medical strategy and clinical development, driving the advancement of Epigenic's clinical programs. Dr. Kelly Shi will lead finance, capital operations, and investor relations, delivering strategic financial guidance and capital market insights to support long-term gowth of the company.
Dr. You is a seasoned expert in global clinical development with over 18 years of experience in translational medicine and clinical development across China, North America, and Europe. She has led full-cycle drug development from IND submission to NDA approval across multiple therapeutic areas, including cardiometabolic diseases, precision medicine in oncology, ischemic disease/regenerative medicine, autoimmune diseases (hematology and nephrology), psychiatry and neurology, and disfiguring diseases. Dr. You has authored more than 20 peer-reviewed SCI publications in internationally renowned academic journals, with cumulative impact factors nearing 300. Prior to Epigenic, she served as Executive Vice President and Head of Clinical Development at Visirna Therapeutics. Dr. You earned her Ph.D. in Biology and Pharmacology from the Faculty of Medicine, Université Paris Cité in France, and medical degree from Tongji Medical College, Huazhong University of Science and Technology in China.
Dr. Shi is a well-recognized Wall Street biotech analyst with a decade of expertise in biopharmaceutical investment research. She has establised deep domain knowledges across a wide range of therapeutic areas, including oncology, immunology & inflammation, ophthalmology, metabolic diseases, and rare diseases. Dr. Shi also brings substantial capital market experience, having worked with many global biotech companies and led research support for their IPO projects on NASDAQ and the Hong Kong Stock Exchange. Previously, she served as Senior Vice President and Senior Biotechnology Equity Research Analyst at Jefferies. Dr. Shi holds a Ph.D. in Cancer Biology from the University of Massachusetts Medical School, an MBA from the Fuqua School of Business at Duke University, and a B.S. in Biology and Computer Science from the University of Science and Technology of China.
Dr. Bob Zhang, Co-Founder & CEO of Epigenic, stated: “We warmly welcome Dr. Chloe You and Dr. Kelly Shi to Epigenic. As we advance our core pipeline’s global clinical development and strategic expansion, Dr. You’s profound expertise in innovative drug clinical development and Dr. Shi’s sharp insights into Wall Street capital markets repreent the critical capabilities we need to accelerate our evolution into a global innovative biotech company. Their appointments will significantly enhance our clinical development efficiency and capital operation capabilities, accelerating our mission to deliver breakthrough therapies to patients worldwide.”
Dr. You commented: “I am honored to join Epigenic at this pivotal stage. The company has established a differentiated pipeline with distinct advantages across multiple disease areas, particularly its clinical-stage assets in cardiometabolic and infectious diseases that align strongly with the unmet medical needs of chronic disease patients globally. I look forward to collaborating closely with the team to advance clinical translation and development of next-generation gene modulation therapy utilizing regulation of epigenetic genome, bringing superior innovative treatments to patients worldwide as soon as possible.”
Dr. Shi said: “Epigenic’s technology competitiveness and growth potential in the emerging epigenetics space are truly impressive. I am excited to join at this important juncture. Leveraging my experience in biopharmaceutical investment and corporate strategy, I will work closely with the team to fortify our capital capabilities, accelerate strategic execution, and build Epigenic into a world-class biotech company.”
About Epigenic Therapeutics
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next-generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering genetic technologies and developing gene modulation therapies, the company has multiple product candidates in the pipeline, including treatments for metabolic, cardiovascular, viral hepatitis, ocular and autoimmune diseases, etc. For more information, please visit www.epigenictx.com
Contact
Partnering@epigenictx.com
Media@epigenictx.com
Investors@epigenictx.com
